Investor Presentaiton

Hematology Cell Therapy Immunology Cardiovascular Oncology Opdualag (anti-LAG3 + anti-PD1 FDC) Indication Phase/Study # of Patients 1L HCC Phase I/II RELATIVITY-106 N = 162 1L Stage IV NSCLC Phase II-CA224-104 N = 420 Design Nivolumab + relatlimab + bevacizumab • Nivolumab + placebo + bevacizumab Endpoints Primary: DLTS, ORR Part I: Nivolumab + relatlimab Dose 1+ PDCT • Nivolumab + relatlimab Dose 2 + PDCT Part II: Nivolumab + relatlimab Dose 2 + PDCT • Nivolumab + PDCT Primary: • Part I: TRAEs leading to discontinuation within 12 weeks after first dose Part II: ORR Projected data readout 2024 • Recruiting Status • Projected data readout 2024 CT Identifier NCT05337137 ll Bristol Myers Squibb™ | Q3 2023 Results NCT04623775 Not for Product Promotional Use 37

View entire presentation